InnoCare Doses First Patient in Soficitinib Urticaria Trial
InnoCare has dosed the first patient in a Phase II/III trial of its oral TYK2 inhibitor soficitinib (ICP-332) for...
Jon Napitupulu
Annovis Alzheimer’s Drug Advances to Pivotal Phase 3 Trial
An independent DSMB found no safety concerns at six months in Annovis Bio’s pivotal Phase 3 Alzheimer’s trial of...
ImmunoSensor Doses First AGS Patient in New Phase 1b Study
Phase 1a data in healthy volunteers showed IMSB301 was well tolerated across a broad dose range, produced dose-dependent and...
Vaxcyte Doses First Adults in VAX-31 Phase 3 Vaccine Trial
In prior adult Phase 1/2 data, VAX-31 produced robust opsonophagocytic activity across all 31 serotypes, met superiority criteria on...
Senti Bio Completes SENTI-202 Phase 1 AML Trial Enrollment
Early Phase 1 signals from Senti Biosciences’ off-the-shelf CAR-NK program in relapsed/refractory AML include MRD-negative, durable complete remissions with...
Upstream Bio Sees Positive Results in Phase 2 Asthma Trial
Upstream Bio’s Phase 2 VALIANT study in severe asthma cut annualized asthma exacerbation rate by 56% with verekitug 100...
Remarkable Results: Microbiotica’s MB310 Colitis Trial
Clinical remission was achieved in 63.2% (12/19) of patients treated with MB310 versus 30.0% (3/10) on placebo in an...
PathAI Expands AISight Platform for IBD Clinical Trials
PathAI has expanded its AISight Clinical Trials platform for inflammatory bowel disease with the launch of IBDExplore, joining its...
Septerna Presents Phase 1 Trial Data for Mast Cell Diseases
Septerna will present first-in-human, proof‑of‑mechanism data for SEP‑631, an oral MRGPRX2 negative allosteric modulator, at the AAAAI Annual Meeting...
FDA Approves Expanded Eligibility for Phase 3 PWS Trial
Aardvark Therapeutics secured U.S. IRB approval to amend its Phase 3 HERO protocol, lowering the minimum enrollment age from...